Frontage Laboratories Inc, a US-based global Contract Research, Development and Manufacturing Organisation (CRDMO) and a subsidiary of Frontage Holdings Corporation (HKEX:1521), said on Friday that it has expanded its early phase clinical research capabilities across the United States and China.

The company said that this strategic growth enhances its ability to support pharmaceutical and biotech partners with accelerated, high-quality clinical development solutions.

Frontage's US operations are anchored by a 160-bed, 36,000-sq-ft Phase I clinical unit in Secaucus, New Jersey, designed to conduct large-scale Phase I and Bioequivalence (BE) studies, as well as radiolabelled human AME research. The company has further strengthened its C14-hAME capabilities through a dedicated unit staffed by licensed radiation experts and supported by an on-site nuclear pharmacy for sterile and non-sterile radiolabelled compounding. Frontage has executed combined hAME and Absolute Bioavailability studies aligned with the FDA's 2024 guidance.

In response to growing industry demand, Frontage is also expanding into Oncology Phase I trials through partnerships with regional hospitals and clinical networks, enabling patient-based research across key cancer indications.

As the industry approaches a significant wave of patent expirations, Frontage's multiple US clinical units are positioned to manage complex, high-volume BE programmes, and collaboration with Frontage China enables flexible Multi-Regional Clinical Trial (MRCT) execution.